Hotgen Single-Test Chemiluminescence MQ60 Series--China's Largest Single-Test Chemiluminescence by Installed Capacity, With Global Coverage in Over 50 Countries and 18,000+ Installations

In today's fast-paced clinical diagnostic environment, laboratories and medical institutions require flexible, accurate, and user-friendly immunoassay solutions. As a professional innovative enterprise in the field of in vitro diagnostics (IVD), Hotgen has launched the MQ60 series of Mono-Test Chemiluminescent Immunoassay platforms (Mono‑Test CLIA) to meet this market demand. This compact fully automated chemiluminescent immunoassay (CLIA) platform has the largest installed base of Mono-Test CLIA in China and can provide high-performance testing solutions for small to medium-sized laboratories, clinics, hospitals, and point-of-care testing (POCT) scenarios worldwide.

The MQ60 series (including the MQ60 smart and MQ60 proB models) is designed for on-demand testing, combining advanced CLIA technology with a practical single-test reagent card system. The system features a small footprint, low maintenance costs, and simple operation, making it particularly suitable for decentralized testing and rapid response testing scenarios.

Chemiluminescent Immunoassay (CLIA) Technology Analysis

CLIA is widely regarded as one of the most sensitive and accurate immunoassay methods available. This technology uses chemiluminescent labels, where the intensity of the luminescent signal is proportional to the concentration of the target biomarker, thus achieving good sensitivity, a wide dynamic range, and high specificity.

The MQ60 series adopts magnetic microparticle separation technology combined with single-test reagent strips. This single-test mode does not require a complex liquid path system, which can reduce maintenance requirements and the risk of cross-contamination. Each test card can operate independently, making the system highly suitable for emergency (STAT) testing and low to medium throughput testing scenarios, while also minimizing reagent waste. Its stable performance in large-scale clinical applications has made the MQ60 one of the most widely used Mono-Test CLIA platforms in China, forming the largest installed base of Mono-Test CLIA.

Core Advantages of Mono-Test CLIA

• Samples can be directly loaded without complex pre-processing

• Fast detection speed (results for some tests as quick as 17 minutes)

• Individually packaged reagent cards with excellent stability

• Built-in quality control mechanisms

• Highly flexible—supports single or small batch testing, avoiding waste

• Compact desktop design suitable for hospitals, clinics, emergency departments, and decentralized laboratories

MQ60 Series: Designed for Real Clinical Needs

The MQ60 series offers two desktop models to meet the needs of laboratories of different sizes:

MQ60 smart

This ultra-compact model boasts a small body and is equipped with an easy-to-operate 10.1-inch touchscreen. The system has 6 independent testing channels, with a testing speed of up to 30 tests per hour. It is ideal for small clinics, satellite laboratories, and medical institutions with moderate daily testing volumes. The system has a built-in computer and thermal printer for seamless operation. Its compact design and single-test mode make it particularly suitable for fast and flexible testing environments.

MQ60 proB

As a higher-performance model, the proB is equipped with 12 testing channels, with a testing speed of up to 60 tests per hour, while still maintaining the compact advantages of a desktop device. The system has larger storage capacity, STAT priority testing function, and a larger 13.3-inch touchscreen, making it suitable for laboratories with higher testing volumes, while still ensuring convenient maintenance and compact design.

Both systems feature precise temperature control, comprehensive LIS/HIS connectivity, 24-hour standby capability, and support for various sample types, including serum, plasma, and whole blood.

Comprehensive Test Menu

The MQ60 series offers a rich single-test CLIA reagent menu to cover various clinical testing needs. Major testing items include cardiac markers, inflammation and infection indicators, thyroid function, tumor markers, hormones, diabetes, kidney function, and liver function, as well as a variety of specialized testing items.

Notably, the platform supports TB‑IGRA tuberculosis infection T-cell testing, which can detect latent and active tuberculosis infections through simple blood samples. The system combines protein extraction reagents with IFN‑γ detection technology to provide accurate, simple, and reliable test results, suitable for both single-test and fully automated testing processes.

Additionally, the system offers a comprehensive solution for gastric disease biomarkers, including G‑17, PG I, PG II, and Helicobacter pylori antibodies, which can be used for early screening and monitoring of gastritis, precancerous lesions, and gastric cancer.

The MQ60 series also supports advanced cytokine detection, covering pro-inflammatory and anti-inflammatory cytokine combinations, suitable for monitoring immune responses, early identification of infections, inflammation, cytokine storms, and sepsis, and providing support for intensive care and tumor clinical applications.

The comprehensive test menu makes the MQ60 series widely applicable to clinical scenarios such as emergency, routine screening, chronic disease management, maternal and child health, and specialized diagnostics. The single-test mode further enhances testing flexibility, allowing laboratories to efficiently complete on-demand testing while avoiding unnecessary reagent consumption.

Key Clinical Advantages

The MQ60 series excels in scenarios with high requirements for speed, simplicity, and reliability:

• Emergency and ICU: Rapid assessment of cardiovascular events, sepsis, cytokine responses, and infections

• Outpatient and primary care: Supports gastric function testing, tuberculosis screening, and routine on-demand testing

• Cost advantage: Single-card testing mode significantly reduces reagent waste and operational costs

• Easy operation: Intuitive interface and low training threshold enable small laboratories to apply CLIA technology

• High reliability: Magnetic microparticle technology and strict quality control systems ensure stable and accurate results

Compared to traditional ELISA or large high-throughput CLIA systems, the MQ60 series achieves a good balance between performance and practicality. Its success in large-scale clinical applications further validates the reliability and scalability of Hotgen's Mono-Test CLIA solutions. Additionally, the system is compatible with fully automated CLIA workflows (including the C800 and C2100 analyzers).

Why Laboratories Choose Hotgen MQ60

Hotgen has always focused on user-centered innovation and has grown into a trusted manufacturer of chemiluminescent immunoassay analyzers. The MQ60 series fully embodies this philosophy, combining compact design, stable performance, and broad applicability. By emphasizing both instrument hardware and high-quality supporting reagents, Hotgen can provide a complete and reliable solution.

As the Mono-Test CLIA platform with the largest installed base in China, the MQ60 series has gained widespread market recognition and accumulated rich clinical application experience. The platform is particularly suitable for small to medium-sized hospitals, independent laboratories, primary care institutions, emergency departments, and intensive care centers. Its CE, ISO, and NMPA certifications further enhance global market recognition and regulatory confidence.

Conclusion: The Smart Choice for Modern Diagnostics

The MQ60 series Mono-Test CLIA platform represents a significant advancement in the widespread application of chemiluminescent immunoassay technology. This system combines high sensitivity, ease of operation, and cost-effectiveness in a compact body, enabling medical institutions of all sizes to obtain timely and accurate test results.

For medical institutions seeking flexible, low-maintenance, and future-oriented immunoassay solutions—especially in TB‑IGRA, gastric function biomarkers, cytokine testing, and routine CLIA projects—the MQ60 smart and MQ60 proB provide an excellent balance between performance and practicality. With the largest installed base of Mono-Test CLIA in China and an expanding global application, the MQ60 series continues to strengthen Hotgen's leading position in the field of innovative CLIA diagnostics.